UCB up 2% as bimekizumab bests Humira

6 December 2019

Shares in Belgian drugmaker UCB (Euronext: UCB) were set to close 2% up on Friday following the presentation of data on the company’s key pipeline asset, bimekizumab.

The BE SURE study, comparing the Interleukin (IL)-17A and IL-17F inhibitor to AbbVie’s mega blockbuster Humira (adalimumab) in moderate-to-severe plaque psoriasis, met all co-primary and ranked secondary endpoints.

BE SURE met its co-primary endpoints at week 16, demonstrating superiority of bimekizumab to adalimumab in achieving at least a 90% improvement in the psoriasis area and severity index (PASI 90) and investigator global assessment response of clear or almost clear.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK